Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant dalpiciclib + pyrotinib + trastuzumab + letrozole for HER2-positive, hormone receptor-positive breast cancer
ChiCTR2200065170Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Oct 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dalpiciclib, pyrotinib, trastuzumab and letrozole in breast cancer, sponsored by First Affiliated Hospital of Soochow University. Primary endpoint: Total pathological complete response. Planned start Oct 2022; status: not yet recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2200065170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200065170.